by Raynovich Rod | Jan 14, 2020 | Biopharmaceuticals, Clinical Diagnostics and Tools
JPM Notes #2 : Investors buy into Life science innovation After a lackluster day Monday the tape for JPM life science sector stocks picked up with a decent rally. Major ETFs reversed the trend from yesterday with the IBB up 1.64% and the XBI up 2.94% despite NASDAQ...
by Raynovich Rod | Nov 24, 2019 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1 11/25/19… Rally right on track driven by NVS/MDCO deal, new product surge and cheap money from FED. As we said many time on this site XBI is the bellwether up 4.25% today (UP 13% in one month) as biotech stocks broke out last week. IBB up 2.46%. We...
by Raynovich Rod | Nov 18, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-3 10/20…China Phase 1 deal stalled -curbs strong momentum in biopharma. Amarin (AMRN) getting beat up by an Oppenheimer skeptic who thinks Vascepa growth will be tepid. Despite tape slowing many stocks saw huge gains: ASND NKTR SRPT etc. Per comment on...
by Raynovich Rod | Nov 12, 2019 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-2…One of the best days of the year for us; I will summarize later. Only laggard sector was speculative microcaps. Some of our best gains among healthcare/life science stocks: ABBV AMRN CRSP GILD ILMN TDOC UNH VCYT XBI ======= Update-1… Biotech gains...
by Raynovich Rod | Oct 10, 2019 | Biopharmaceuticals
Update-2 10/13…Biotech IPOs Remain Weak-Recent rally was weak for small cap biotechs Vir Biotechnology (VIR): A clinical stage immunology and infectious disease Company focused on new therapies for hepatitis (HBV), Influenza A, HIV and TB went public on Friday....
by Raynovich Rod | Oct 2, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
Update-2 10/4 Broad Rally day: all major averages up 1.4%, NAZ at 7982. Risk back on. But biotech lags major indices IBB up 0.75%, XBI up 0.21% to $76.82. Better trade for biotech has been large caps: ABBV, AMGN, MRK,RHHBY VRTX. Mid-cap movers: BLUE up 3.97%, GWPH up...
by Raynovich Rod | Aug 12, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
Update-3…8/16 Big reversal day…summary this weekend with XBI up 2.65% at $82.46 just above support. Update-2… 8/14 Nowhere to hide from Global economic fears-welcome to whipsaw trading. Technicals matter not tweets. Market averages down about 3%...
by Raynovich Rod | Jun 30, 2019 | Biopharmaceuticals
Update-1 A bit of a sell-off in gene therapy but MGTX at new highs at $29.44. Profit taking on Sarepta down 3.84% to $150.59. Roche (RHHBY) and Merck (MRK) near new highs. Mid-caps mixed but Novacure (NVCR) rally 3.27% toward new highs. One of our top picks Amarin...
by Raynovich Rod | Jun 24, 2019 | Biopharmaceuticals, Macro
Update-2… 6/27 2p EDT…Good day for gene therapy stocks My longs CRSP and MGTX are up. Looking better all across the screen in biopharma. Added to ABBV and XNCR yesterday. XBI up but still under $86. Update-1… Another Big Deal in Biotech in a weak...
by Raynovich Rod | Jun 10, 2019 | Biopharmaceuticals, Macro
Update-3 6/17 11:30 a EDT Pfizer (PFE) $11B Buyout of Array Pharmaceuticals (ARRY) Sparks Rally in biotech. As usual M&A brings buyers into biotech. ARRY up 56% on Pfizer $11B buyout. XBI up 3.68% to $84.46. Green screen in mid-caps, gene therapy. ==========...